The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
Japanese biotech Healios said on April 4 that it has completed the purchase of substantially all assets of Athersys after the US firm filed for bankruptcy early this year. This makes Healios now the sole owner of the off-the-shelf cell…
To read the full story
Related Article
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- Healios Again Delays Definitive MultiStem Deal with Nobelpharma
October 1, 2024
- Healios, FDA Agree on Pivotal PIII Design for Cell Therapy MultiStem
September 10, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
BUSINESS
- iPark Institute to Launch AI-Based Platform to Link Investors with Startups
January 16, 2026
- Acromegaly Drug Palsonify Meets Primary Endpoint in Japan PII/PIII Trial
January 16, 2026
- Tanabe’s EPP/XLP Drug Hits Main Goals in PIII, Weighs Launch Strategy
January 16, 2026
- Forxiga Generics Reach 11% Share in First Month: Intage
January 16, 2026
- Takeda to Halt Sales of Cell Therapy Alofisel in Japan
January 15, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…